Target Therapy of Cholangiocarcinoma Using Sirna Silencing Eukaryotic Initiation Factor 4e and Cyclin D1

The incidence of cholangiocarcinoma (ICC) is increasing worldwide, generally representing between 5 and 30% of primary liver cancers. Few patients are fit for curative resection. ICC is refractory to conventional chemotherapy and radiation therapy. Therefore, a novel therapeutic strategy is eagerly desirable. In this 3-year proposal, we attempt to develop a new therapeutic strategy to treat ICC by silencing eukaryotic initiation factor4E (eIF4E) and cyclin D1. Rationale: We have shown overexpression of eIF4E in human cholangiocarcinoma (Figure 1), which regulates cell cycles. The works we wish to achieve: 1. To determine expression of eIF4E and cyclin D1 in human cholangiocarcinoma, cholangiocarcinoma cell lines. 2. To establish thioacetamide-induced rat cholangiocarcinoma and determine the expression of eIF4E and cyclin D1 of rat cholangiocarcinoma. 3. To establish stable siRNA against eIF4E and cyclin D1 3. In vitro test, to treat cholangiocarcinoma cell lines using siRNA silencing eIF4E and cyclin D1. 4. In vivo test, to treat rat cholangiocarcinoma using siRNA silencing eIF4E and cyclin D1.

Project ID:PC9706-0483
External Project ID:NSC96-2314-B182-010-MY3